iBio (NYSE:IBIO – Get Free Report) and PyroGenesis Canada (NASDAQ:PYRGF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Profitability
This table compares iBio and PyroGenesis Canada’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -73.15% | -45.51% |
| PyroGenesis Canada | -115.14% | N/A | -60.81% |
Risk & Volatility
iBio has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $500,000.00 | 85.00 | -$24.91 million | ($1.39) | -1.36 |
| PyroGenesis Canada | $9.14 million | 5.85 | -$21.12 million | ($0.03) | -8.81 |
PyroGenesis Canada has higher revenue and earnings than iBio. PyroGenesis Canada is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
7.9% of iBio shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for iBio and PyroGenesis Canada, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 0 | 0 | 3 | 0 | 3.00 |
| PyroGenesis Canada | 0 | 0 | 0 | 0 | 0.00 |
iBio currently has a consensus target price of $4.00, indicating a potential upside of 111.64%. Given iBio’s stronger consensus rating and higher probable upside, research analysts plainly believe iBio is more favorable than PyroGenesis Canada.
Summary
iBio beats PyroGenesis Canada on 9 of the 14 factors compared between the two stocks.
About iBio
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
About PyroGenesis Canada
PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
